HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

Running, not enrolling · Phase 1

Conditions studied: Ependymoma

In brief

This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children. The HER2 CAR T cells used in this trial are made from the patient's own blood. A new gene, called the HER2 CAR, will be inserted into patient's T cells to allow them recognize a protein on the tumor called HER2. These HER2-specific CAR T cells may be able to target and kill ependymoma tumors that express HER2. This research is also studying how doable it is to provide this type of CAR T cell treatment to children being treated at different hospitals.

Key facts

Study ID
NCT04903080
Run by
Children's Oncology Group
People needed
50
Starts
2022-07-27
Expected to finish
2033-03-31
Last updated by the study team
2026-06-02

Who can join

Age: 1 and older, up to 22. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.